Tianda Pharmaceuticals Ltd. (HK:0455) has released an update.
Tianda Pharmaceuticals Ltd. has issued a profit warning, anticipating a significant decrease in revenue by over 48% and an increased loss of at least HK$27 million in the first half of 2024 compared to the same period in 2023. The downturn is attributed to reduced demand for its pediatric drug post-pandemic and competitive pricing pressures in the cardio-cerebrovascular drug market. Investors are advised to exercise caution when dealing with the company’s securities.
For further insights into HK:0455 stock, check out TipRanks’ Stock Analysis page.
